Rivaroxaban, a non-vitamin K antagonist (VKA) oral anticoagulant, was found to have better persistence and lower discontinuation rates than, the VKA warfarin and the non-VKA, dabigatran.
Your search for Warfarin returned 8 results
There is a higher incidence rate of intracranial bleeding than previously thought, in older patients who initiate warfarin therapy for atrial fibrillation (AF), suggesting that greater individual factors should be discussed with patients before warfarin administration begins.
Over 1.1 million packages of test strips distributed from January 12, 2018 to October 29, 2018 are being recalled.
A new report highlights the potential risk in concomitant use of the anticoagulant dabigatran, and phenytoin, a P-glycoprotein (P-gp) inducer used to treat seizure disorders.
Terrific Care/Medex Supply had purchased these test strips (which were distributed by Roche Diagnostics outside the country) from an unknown source, imported and sold them in the US.
The Food and Drug Administration (FDA) is warning patients and caregivers not to use test strips from previous owners or ones not authorized for sale in the US.
Forty-eight percent of atrial fibrillation (AF) patients, who are at the highest risk of stroke, were not prescribed oral anticoagulant (OAC) medication.
Treatment recommendations were made taking into account the possibility of reduced glomerular filtration rate and drug-drug interactions.